Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.

No abstract is available for this paper.

• Publication year

  1984

• Venue

  Journal of Clinical Oncology

• Publication date

  1984-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1984.2.12.1321PMID 6542584
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma.

  1984cited by this paper
• A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate.

  1984cited by this paper
• Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation).

  1983cited by this paper
• Intraperitoneal cisplatin with systemic thiosulfate protection.

  1982cited by this paper
• Phase I and Pharmacological Studies of Adriamycin Administered Intraperitoneally to Patients with Ovarian Cancer

  1982cited by this paper
• Chemotherapy of advanced ovarian carcinoma: Initial experience using a platinum‐based combination

  1982cited by this paper
• Epithelial carcinoma of the ovary: current strategies.

  1981cited by this paper
• High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.

  1981cited by this paper
• Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro.

  1981cited by this paper
• Determination of cytarabine and uracil arabinoside in human plasma and cerebrospinal fluid by high-performance liquid chromatography.

  1981cited by this paper
• Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine.

  1981cited by this paper
• Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.

  1981cited by this paper
• Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.

  1980cited by this paper
• Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy.

  1980cited by this paper
• Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.

  1980cited by this paper
• Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics.

  1979cited by this paper
• Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

  1978cited by this paper
• Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

  1978cited by this paper

• Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer

  2021cites this paper
• DDDT_A_311187 2857..2868

  2021cites this paper
• Pentamidine Inhibits Ovarian Cancer Cell Proliferation and Migration by Maintaining Stability of PTEN in vitro

  2021cites this paper
• Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution

  2017cites this paper
• Preventing recurrence of diffuse malignant peritoneal mesothelioma

  2016cites this paper
• Intraperitoneal Chemotherapy For The Treatment Of Malignant Peritoneal Mesothelioma

  2015cites this paper
• Intraperitoneal Chemotherapy For The Treatment Of Malignant Peritoneal Mesothelioma

  2013cites this paper
• Intraperitoneal Chemotherapy For The T reatment Of Malignant Peritoneal Mesothelioma

  2013cites this paper
• Quantitative X-ray Computed Tomography Peritoneography in Malignant Peritoneal Mesothelioma Patients Receiving Intraperitoneal Chemotherapy

  2013cites this paper
• Smart Packaging: A Novel Technique For Localized Drug Delivery For Ovarian Cancer

  2012influential citation
• The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography–inductively coupled plasma mass spectrometry

  2008cites this paper
• Oncodiagnosis Panel: 2006. Ovarian, cervical, and endometrial cancer.

  2008cites this paper
• Strategies to examine new compounds for intraperitoneal use in ovarian cancer

  2008cites this paper
• Inductively coupled plasma mass spectrometry: a unique, ultrasensitive tool for exploring the pharmacology of metal-based anticancer agents

  2007cites this paper
• Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?

  2007cites this paper
• EF24 Induces G2/M Arrest and Apoptosis in Cisplatin-resistant Human Ovarian Cancer Cells by Increasing PTEN Expression*

  2007cites this paper
• The role of intraperitoneal therapy in advanced ovarian cancer.

  2007cites this paper
• Management of Ovarian Cancer: Clinical Trials

  2007cites this paper
• Current status of intraperitoneal antineoplastic drug delivery.

  2007cites this paper
• Management of Ovarian Cancer: The Theory

  2007cites this paper
• Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.

  2006cites this paper
• Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer

  2006cites this paper
• Phase I and pharmacokinetic study of intraperitoneal topotecan

  2004cites this paper
• Chemotherapy in malignant mesothelioma: a review

  2004cites this paper
• Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy

  2003cites this paper
• Laparoscopical insertion of intraperitoneal catheters for intraperitoneal chemotherapy

  2003cites this paper
• Intraperitoneal cisplatin versus no further treatment: 8‐year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum‐based intravenous chemotherapy

  2003cites this paper
• Intraperitoneal chemotherapy in ovarian cancer.

  2000cites this paper
• Intraperitoneal Chemotherapy in Management of Peritoneal Mesothelioma

  2000cites this paper
• Treatment of Malignant Ascites

  1999cites this paper
• Maligne Tumoren der Ovarien

  1998cites this paper
• Pharmacological basis for a novel therapeutic strategy based on the use of aquated cisplatin.

  1997cites this paper
• Palliative Radiation Therapy in Female Genital Cancers

  1997cites this paper
• Peritoneal-plasma barrier.

  1996cites this paper
• Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma.

  1996cites this paper
• Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.

  1994cites this paper
• Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma

  1994cites this paper
• Cisplatin: a clinical review. Part I--Current uses of cisplatin and administration guidelines.

  1994cites this paper
• The effect of prolonged cisplatin‐based chemotherapy on progression‐free survival in patients with optimal epithelial ovarian cancer: ‘Maintenance’ therapy reconsidered

  1993cites this paper
• Role of autotransplantation in treatment of other solid tumors.

  1993cites this paper
• Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity.

  1993cites this paper
• Guanosine potentiates the antiproliferative effect of cytosine-beta-D-arabinofuranoside in melanoma cell lines.

  1993cites this paper
• Phase I and pharmacokinetic study of intraperitoneal ormaplatin.

  1993cites this paper
• The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered.

  1992cites this paper
• Sequential cisplatin-doxorubicin, early debulking surgery and intraperitoneal chemotherapy in advanced ovarian cancer. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).

  1992cites this paper
• Survival with Intraperitoneal Cisplatin in Advanced Ovarian Cancer after Second‐Look Laparotomy

  1992cites this paper
• The clinical pharmacology of cytotoxic drugs in gynaecology

  1991cites this paper
• Development of lung metastases after curative intraperitoneal chemotherapy in a rat colon cancer model.

  1991cites this paper
• Concomitant whole‐abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma. A pilot study

  1991cites this paper
• Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.

  1991cites this paper
• Identification of tumor necrosis factor and lymphotoxin blocking factor(s) in the ascites of patients with advanced and recurrent ovarian cancer.

  1991cites this paper
• Intraperitoneal antineoplastic agents in the management of ovarian cancer.

  1991cites this paper
• New chemotherapies for ovarian cancer. Systemic and intraperitoneal podophyllotoxins

  1991cites this paper
• An experimental model for advanced ovarian cancer.

  1990cites this paper
• Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.

  1990cites this paper
• Implantable Drainage After Major Abdominal Surgery in Compromised Patients

  1990cites this paper
• High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.

  1990cites this paper
• Clinical correlations with chemosensitivities measured in a simplified tritiated thymidine incorporation assay in patients with malignant effusion.

  1990cites this paper
• A review: intraperitoneal cisplatin in the management of patients with ovarian cancer.

  1990cites this paper
• Predictors of recurrent disease after negative second‐look laparotomy for epithelial ovarian cancer

  1990cites this paper
• Experimental and clinical status of intraperitoneal chemotherapy.

  1990cites this paper
• Reduction of the local toxicity of intraperitoneal chemotherapy; an experimental model

  1990cites this paper
• Biochemical modulation of cisplatin toxicity.

  1989cites this paper
• Abdominal Leiomyosarcoma: Aggressive Management

  1989cites this paper
• A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer.

  1989cites this paper
• Intraperitoneal therapy in the management of ovarian carcinoma.

  1989cites this paper
• Transport and metabolism of 1-beta-D-arabinofuranosylcytosine in human ovarian adenocarcinoma cells.

  1989cites this paper
• First‐Line Chemotherapy with Intraperitoneal Cisplatin and Intravenous Cyclophosphamide in Ovarian Carcinoma: A Preliminary Report

  1989cites this paper
• Re-Treatment of Patients With Recurrent Epithelial Ovarian Cancer With Cisplatin-Based Chemotherapy

  1989cites this paper
• Management of recurrent ovarian carcinoma.

  1989cites this paper
• Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma.

  1988cites this paper
• Pharmacokinetics ofcis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (iproplatinum, chip) in patients with normal and impaired renal function and following intraperitoneal administration

  1988cites this paper
• Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma

  1988cites this paper
• The surgical complications of chemotherapy in the cancer patient.

  1987cites this paper
• Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model.

  1987cites this paper
• Synergistic effects of cis-platinum and cytosine arabinoside on ovarian carcinoma cell lines, demonstrated by dual-parameter flow cytometry.

  1987cites this paper
• The pharmacology of intraperitoneally administered bleomycin.

  1987cites this paper
• Ovarian cancer

  1987cites this paper
• Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia.

  1987cites this paper
• Intraperitoneal chemotherapy for ovarian carcinoma.

  1987cites this paper
• Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.

  1987cites this paper
• Cerebellar metastases from epithelial ovarian carcinoma. A case report.

  1987cites this paper
• Intraperitoneal chemotherapy for malignant diseases of the gastrointestinal tract.

  1987cites this paper
• Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.

  1987cites this paper
• Intraperitoneal “Belly Bath” Chemotherapy

  1987cites this paper
• Intraperitoneal chemotherapy: Principles and results of clinical trials

  1987cites this paper
• Concepts in intraperitoneal chemotherapy.

  1987cites this paper
• Implantable devices for chemotherapy: access and delivery.

  1987cites this paper
• High‐Dose Chemotherapy Concepts and Strategies

  1987cites this paper
• The intracavitary administration of cytarabine to patients with nonhematopoietic malignancies: an update.

  1987cites this paper
• Intraperitoneal chemotherapy in ovarian carcinoma.

  1987cites this paper
• Second‐Line Chemotherapy for Ovarian Cancer

  1986cites this paper
• The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy.

  1986cites this paper
• Review: Advances in Intraperitoneal (Intracavitary) Administration of Synthetic Polymers for Immunotherapy and Chemotherapy

  1986cites this paper
• [Effective treatment of peritoneal carcinosis by intraperitoneal cis-diamminedichloroplatinum (c-DDP) administration with systemic sodium thiosulfate protection. Clinical results and pharmacokinetics].

  1986cites this paper
• Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma

  1986cites this paper
• Peritoneal Access for Intracavitary Chemotherapy

  1986cites this paper
• Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences.

  1986cites this paper
• Effektivere Behandlung der Peritonealkarzinose durch intraperitoneale Cis-Diamindichloroplatin (c-DDP)-Gabe mit systemischer Natriumthiosulfatprotektion

  1986cites this paper
• Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin.

  1986cites this paper